Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
705 (USA) · Dr. Muller
consented 2013-09-16
AEs
2
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Moderate DYSPEPSIA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-09-17 (study day 2.0); relationship: POSSIBLE
moderate
assessed
Moderate DYSPEPSIA — outcome: RECOVERED/RESOLVED; onset 2013-09-17 (study day 2.0); relationship: POSSIBLE
Data queries
No data queries.